Zachary Zumsteg on early phase trial design for novel drug-radiotherapy combination

May Abdel-Wahab and Andrew Scott on The Lancet Oncology Commission on Radiotherapy and Theranostics

Kanwal Raghav on trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02)

Emmy Boerrigter on dose selection of novel anticancer drugs

Hisham Mehanna and Sue Yom on head and neck cancer consensus recommendations

Garth Strohbehn and Katie Lichter on the environmental impact of cancer treatment

James Shultz, Ana Patricia Ortiz, and Leticia Nogueira on cancer and compounding disasters in the Caribbean

Bernardo Goulart on correlations of endpoints in lung cancer immunotherapy trials

Maria Kyrgiou on innovations in gynaecological cancers and global disparities

Georgios Lyratzopoulos on the use of chemotherapy and radiotherapy in patients with eight common cancers

Mike Sathekge on radioligand therapy of metastatic castration-resistant prostate cancer

Shankar Siva on stereotactic body radiotherapy for primary renal cell carcinoma

Neerja Bhatla on a new quadrivalent HPV vaccine

Chandra Are on the Lancet Oncology Commission on Global Cancer Surgery

Philipp Karschnia on tissue sampling and processing during resection of diffuse intracranial glioma

Wanda Cui on measuring ovarian toxicity

Ticiana Leal on Tumour Treating Fields

Xuesong Han on cancer diagnosis during the COVID-19 pandemic in the USA

Carlos Fernández de Larrea and Damian Green on BCMA CAR T cells in multiple myeloma

Madeline Pe on the SISAQOL initiative